TrialClinical pharmacology and therapeutics2025

Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.

Jincheng Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.